Cindy Condray, APRN
Women's Health · Topeka, KSNPI 1932675162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $229, more than ten times the $12 reported in 2021.
Across 51 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$156
- Novo Nordisk$142
- Lilly USA, LLC$77
- AstraZeneca$75
- AbbVie$75
- Amgen$63
- plus $271 from 10 others
What the payments were for
- Food & beverage$858100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 9 | $156 |
| Novo Nordisk | 9 | $142 |
| Lilly USA, LLC | 5 | $77 |
| AstraZeneca | 5 | $75 |
| AbbVie | 4 | $75 |
| Amgen | 4 | $63 |
| GSK | 3 | $49 |
| Merck | 2 | $36 |
| Dexcom, Inc. | 1 | $35 |
| Myriad Genetic Laboratories, Inc. | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $19 |
| Boston Scientific | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $14 |
How this compares
$858 in reported general payments places this provider in the 75th percentile of 43 women's health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $35,098 |
| JardianceEmpagliflozin | 25 | $31,050 |
| EliquisApixaban | 20 | $18,951 |
| MyrbetriqMirabegron | 12 | $15,959 |
| MounjaroTirzepatide | 15 | $13,274 |
| FarxigaDapagliflozin Propanediol | 12 | $11,677 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,288 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,138 |
| Atorvastatin Calcium | 396 | $2,959 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,676 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $2,562 |
| Levothyroxine Sodium | 282 | $2,498 |
| Gabapentin | 119 | $2,101 |
| Bupropion XlBupropion Hcl | 44 | $1,992 |
| Losartan Potassium | 195 | $1,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $142 | $35,09819 claims |
| PfizerEliquis | $156 | $18,95120 claims |
| AstraZenecaFarxiga, Symbicort | $75 | $17,96527 claims |
| Lilly USA, LLCMounjaro | $77 | $13,27415 claims |
| GSKBreo Ellipta | $49 | $5,13813 claims |
| AbbVieSynthroid | $75 | $1,56327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 women's health providers in Kansas.
Other women's health in Topeka
- Shannon SchwartzTopeka$623
- Patricia SmithTopeka$101
- Stacy CorumMerriam$4K
- Marcia SnodgrassDodge City$3K
- Julie BiermannOverland Park$3K
- Jennifer PeppardMerriam$2K
- Brandi MulryanOverland Park$2K
- Patricia ArnoldMerriam$2K
- Diane WendelkenManhattan$2K
- Jessica FergasonOverland Park$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.